ERBB2 and cancer: The prognosis of HER2+ cancers has also been revolutionized by the development of increasingly effective treatments targeting HER2, such as ADCs (e.g., Trastuzumab Deruxtecan and Trastuzumab Emtasine) [78,79,80] or tyrosine kinase inhibitors (such as Tucatinib in combination with Trastuzumab and Capecitabine) [81].